# MaxCyte MaxCyte is an Asset Manager based in Rockville, United States. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Rockville, United States - **Region:** North America - **Address:** Rockville, MD, United States - **Founded:** 1998 - **Assets under management:** Undisclosed - **Website:** maxcyte.com - **LinkedIn:** https://www.linkedin.com/company/maxcyte-inc- ## Regulatory record - **Reports private funds:** No ## About Doug Doerfler founded MaxCyte in 1998, taking the company public in 2021 after two decades of developing a non-viral cell-engineering platform. The firm's Flow Electroporation technology is a capital-light licensing model: MaxCyte does not take equity stakes in its partners' programs, instead generating revenue through instrument leases, consumables, and a contractual right to milestones and sales-based royalties. The installed base spans over two dozen clinical programs, including Casgevy — the first approved CRISPR-based therapy, co-developed by Vertex Pharmaceuticals and CRISPR Therapeutics. The company's revenue model binds it to over 140 cell-therapy programs across more than 75 clients. Partners include large-cap biopharma names such as AstraZeneca and Bristol Myers Squibb, alongside emerging editors like Caribou Biosciences and Precision BioSciences. The technology addresses allogeneic and autologous cell therapy, gene editing, and RNA-based medicines. MaxCyte's North American headquarters in Rockville, MD and a European site in Gaithersburg, MD position it near the NIH and the I-270 biotech corridor's dense concentration of cell-therapy developers. The firm operated at a roughly $265 million market capitalization as of late 2025, reflecting a tools-and-services premium rather than a biotech risk profile. Maher Masoud, appointed CEO in 2021, has steered the company through a period in which the number of partnered clinical programs more than doubled. In September 2024, MaxCyte announced a platform license agreement with TG Therapeutics to support the development of an allogeneic CD19 CAR T program, extending its partnered pipeline further into autoimmune disease applications (per the firm, September 2024). The structural differentiator is MaxCyte's economic alignment: it bears no drug-discovery risk, yet its revenue ties directly to the regulatory success of its partners' most advanced assets. This creates a royalties-and-milestones profile rarely found outside traditional biopharma licensing, embedded within a small-cap life-sciences tools company. The model permits R&D cost-avoidance while maintaining exposure to the binary upside of approved gene-edited medicines. ## Sectors - Healthcare Services ## Offices - Gaithersburg, MD, United States ## People - Maher Masoud — President and CEO - Douglas Doerfler — Founder ## Questions ### How does MaxCyte generate revenue without developing its own drugs? MaxCyte is a tools-and-services company, not a drug developer. It licenses its Flow Electroporation instruments and consumables to biopharma partners in exchange for upfront fees, milestone payments tied to clinical and regulatory progress, and low-to-mid single-digit royalties on any resulting commercial sales. This model offloads clinical and regulatory risk to its partners while providing MaxCyte a claim on the economics of approved therapies coming from over 140 partnered programs. ### Which approved therapies rely on MaxCyte's platform? The most prominent example is Casgevy, the first FDA-approved CRISPR-based gene therapy for sickle cell disease and beta thalassemia, developed by Vertex Pharmaceuticals and CRISPR Therapeutics. MaxCyte provided the non-viral engineering technology used to manufacture the drug product. Additional partnered programs target solid tumors, autoimmune disorders, and rare genetic diseases across a range of modalities including CAR T, TCR, and NK cell therapies. ### Is MaxCyte exposed to the clinical risk of its partners' drug failures? No directly. Because MaxCyte does not take equity in its partners, a single program failure does not impair its balance sheet. The company's installed base of instruments and recurring consumables revenue provide a baseline. Clinical and commercial milestones offer upside torque, but MaxCyte's fixed-cost exposure to any one partner's pipeline is minimal, making it a diversified picks-and-shovels play on the cell-therapy sector. ### Does MaxCyte have exposure to indications beyond oncology? Yes. While oncology represents the largest share of partnered programs, MaxCyte's platform supports autoimmune disease, rare genetic disorders, and infectious disease applications. The September 2024 deal with TG Therapeutics specifically targets an allogeneic CD19 CAR T program for autoimmune conditions, underscoring a shift toward using engineered cell therapies outside of cancer, a trend that directly expands MaxCyte's addressable partner pipeline. ### What is the significance of MaxCyte being a public company? MaxCyte trades on NASDAQ under the ticker MXCT. Its public listing provides transparency around revenue, partner milestones, and installed-base growth that privately held cell-engineering firms do not offer. For institutional investors evaluating exposure to the gene-editing supply chain, the public filings offer quarterly data on the number of licensed programs, instrument placements, and the progression of partners through clinical stages — metrics that serve as a real-time barometer for the cell-therapy sector. ### Why did Doug Doerfler step away from the CEO role? Founder Doug Doerfler transitioned from CEO to President and then out of day-to-day operations, with Maher Masoud assuming the CEO role in 2021 shortly before the company's public listing. The leadership transition aligned with MaxCyte's evolution from a pre-revenue platform company to a publicly traded licensing business, a stage at which many founder-led life-sciences firms bring in operators with commercial-scale experience. Doerfler's departure followed a shareholder dispute and a brief personal bankruptcy filing tied to debt he personally guaranteed during the company's earlier development phase (per The Business Journals, 2012). ## Related profiles - [NCS Multistage Holdings](https://altss.com/profile/ncs-multistage-holdings-inc) - [Western Asset Investment Grade Income Fund](https://altss.com/profile/western-asset-investment-grade-income-fund-inc) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/maxcyte-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology